Identical twins discordant for type 1 diabetes show a different pattern of in vitro CD56+ cell activation

Diabetes/Metabolism Research and Reviews

Volumn 22, Issue 5, 2006, Pages 367-375

  Goodier, Martin R ^a   Nawroly, Niga ^b   Beyan, Huriya ^c   Hawa, Mohammed ^c   Leslie, R David G ^c   Londei, Marco ^d  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Diabetes; Human; NK cells

Indexed keywords

CD3 ANTIGEN; CD56 ANTIGEN; CD94 ANTIGEN; INSULIN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; LIPOPOLYSACCHARIDE; MESSENGER RNA;

ADULT; ARTICLE; CELL ISOLATION; CONTROLLED STUDY; CORRELATION FUNCTION; DIABETOGENESIS; DISEASE PREDISPOSITION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MONOZYGOTIC TWINS; NATURAL KILLER T CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE ACTIVATION; TWIN DISCORDANCE;

ANTIGENS, CD56; CELL CULTURE TECHNIQUES; DIABETES MELLITUS, TYPE 1; DISEASES IN TWINS; HUMANS; KILLER CELLS, NATURAL; LIPOPOLYSACCHARIDES; LYMPHOCYTE ACTIVATION; MONOMERIC GTP-BINDING PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TWINS, MONOZYGOTIC;

EID: 33749007404     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.627     Document Type: Article

References (31)

1. Bach JF. Non-Th2 regulatory T-cell control of Th1 autoimmunity. Scand J Immunol 2001; 54(1-2): 21-29.
2. Poulton LD, Smyth MJ, Hawke CG, et al. Cytometric and functional analyses of NK and NKT cell deficiencies in NOD mice. Int Immunol 2001; 13(7): 887-896.
3. Wilson SB, Kent SC, Patton KT, et al. Extreme Th1 bias of invariant Valpha24,JalphaQ T cells in type 1 diabetes. Nature 1998; 391(6663): 177-181.
4. Smeltz RB, Wolf NA, Swanborg RH. Inhibition of autoimmune T cell responses in the DA rat by bone marrow-derived NK cells in vitro: implications for autoimmunity. J Immunol 1999; 163(3): 1390-1397.
5. Todd DJ, Forsberg EM, Greiner DL, Mordes JP, Rossini AA, Bortell R. Deficiencies in gut NK cell number and function precede diabetes onset in BB rats. J Immunol 2004; 172(9): 5356-5362.
6. Ogasawara K, Hamerman JA, Hsin H, et al. Impairment of NK cell function by NKG2D modulation in NOD mice. Immunity 2003; 18(1): 41-51.
7. Johansson SE, Hall H, Bjorklund J, Hoglund P. Broadly impaired NK cell function in non-obese diabetic mice is partially restored by NK cell activation in vivo and by IL-12/IL-18 in vitro. Int Immunol 2004; 16(1): 1-11.
8. Lee IF, Qin H, Trudeau J, Dutz J, Tan R. Regulation of autoimmune diabetes by complete Freund's adjuvant is mediated by NK cells. J Immunol 2004, 172(2): 937-942.
9. Poirot L, Benoist C, Mathis D. Natural killer cells distinguish innocuous and destructive forms of pancreatic islet autoimmunity. Proc Natl Acad Sci U S A 2004; 101: 8102-8107.
10. Hussain MJ, Alviggi L, Millward BA, Leslie RD, Pyke DA, Vergani D. Evidence that the reduced number of natural killer cells in type 1 (insulin-dependent) diabetes may be genetically determined. Diabetologia 1987; 30(12): 907-911.
11. Goodier MR, Londei M. Lipopolysaccharide stimulates the proliferation of human CD56+ CD3- NK cells: a regulatory role of monocytes and IL-10. J Immunol 2000; 165(1): 139-147, JID - 2985117R.
12. Goodier MR, Londei M. CD28 is not directly involved in the response of human CD3- CD56+ natural killer cells to lipopolysaccharide: a role for T cells. Immunology 2004, 111(4): 384-390.
13. Hawa M, Rowe R, Lan MS, et al. Value of antibodies to islet protein tyrosine phosphatase-like molecule in predicting type 1 diabetes. Diabetes 1997; 46(8): 1270-1275.
14. Redondo MJ, Yu L, Hawa M, et al. Heterogeneity of type I diabetes: analysis of monozygotic twins in Great Britain and the United States. Diabetologia 2001; 44(3): 354-362.
15. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979; 28: 1039-1057.
16. Urberg M, Valiante NM, Shum BP, et al. Human diversity in killer cell inhibitory receptor genes. Immunity 1997; 7(6): 753-763.
17. Dunne J, Lynch S, O'Farrelly C. et al. Selective expansion and partial activation of human NK cells and NK receptor-positive T cells by IL-2 and IL-15. J Immunol 2001; 167(6): 3129-3138.
18. Loza MJ, Perussia B. The IL-12 signature: NK cell terminal CD56+high stage and effector functions. J Immunol 2004; 172(1): 88-96.
19. Huard B, Karlsson L, Triebel F. KIR down-regulation on NK cells is associated with down-regulation of activating receptors and NK cell inactivation. Eur J Immunol 2001; 31(6): 1728-1735, JID - 1273201.
20. Roep BO, Atkinson M, von Herrath M. Satisfaction (not) guaranteed: re-evaluating the use of animal models of type 1 diabetes. Nat Rev Immunol 2004; 4(12): 989-997.
21. Mestas J, Hughes CC. Of mice and not men: differences between mouse and human immunology. J Immunol 2004; 172(5): 2731-2738.
22. von Kanel R, Mills PJ, Dimsdale JE. Short-term hyperglycemia induces lymphopenia and lymphocyte subset redistribution. Life Sci 2001; 69(3): 255-262.
23. Beyan H, Buckley LR, Yousaf N. Londei M, Leslie RD. A role for innate immunity in type 1 diabetes? Diabetes Metab Res Rev 2003; 19(2): 89-100.
24. Glowacka E, Banasik M, Lewkowicz P, Tchorzewski H. The effect of LPS on neutrophils from patients with high risk of type 1 diabetes mellitus in relation to IL-8, IL-10 and IL-12 production and apoptosis in vitro. Scand J Immunol 2002; 55 (2): 210-217.
25. Plesner A, Greenbaum CJ, Gaur LK, Ernst RK, Lernmark A. Macrophages from high-risk HLA-DQB1*0201/*0302 type 1 diabetes mellitus patients are hypersensitive to lipopolysaccbaride stimulation. Scand J Immunol 2002; 56(5): 522-529.
26. Rabinovitch A. An update on cytokines in the pathogenesis of insulin-dependent diabetes mellitus. Diabetes Metab Rev 1998; 14(2): 129-151.
27. Cooper MA, Felmiger TA, Turner SC, et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood 2001; 97(10): 3146-3151.
28. Peritt D, Robertson S, Gri G, Showe L, Aste-Amezaga M, Trinchieri G. Differentiation of human NK cells into NK1 and NK2 subsets. J Immunol 1998; 161(11): 5821-5824.
29. Vitale M, Della Chiesa M, Carlomagno S, et al. The small subset of CD56 bright CD16- natural killer cells is selectively responsible for both cell proliferation and interferon-gamma production upon interaction with dendritic cells. Eur J Immunol 2004; 34(6): 1715-1722.
30. Takahashi K, Miyake S, Kondo T, et al. Natural killer type 2 bias in remission of multiple sclerosis. J Clin Invest 2001; 107(5): R23-R29.
31. Lee PT, Putnam A, Benlagha K, Teyton L, Gottlieb PA, Bendelac A. Testing the NKT cell hypothesis of human IDDM pathogenesis. J Clin Invest 2002; 110(6): 793-800.